T1	Participants 119 194	131 patients with stage II-III-IV squamous cell carcinoma of the oropharynx
T2	Participants 702 740	A total of 116 patients were evaluable
T3	Participants 742 780	Of 55 patients in the chemotherapy arm
T4	Participants 936 1047	76% (42 of 55) of patients in the experimental group were in CR compared to 89% (54 of 61) in the control group
T5	Participants 1159 1249	median survival was 22 months in the chemotherapy group and 29 months in the control group
T6	Participants 1251 1277	Responders to chemotherapy
T7	Participants 1432 1443	35 patients
